Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections

Transfusion

Volumn 53, Issue 5, 2013, Pages 1088-1094

  Ziemann, Malte ^a   Heuft, Hans Gert ^b   Frank, Kerstin ^b   Kraas, Sabine ^b   Görg, Siegfried ^b   Hennig, Holger ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; PREVALENCE; PRIMARY INFECTION; RISK ASSESSMENT; SEROCONVERSION; TORQUE TENO VIRUS INFECTION; WESTERN BLOTTING;

ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; BLOOD DONORS; BLOOD SAFETY; BLOTTING, WESTERN; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FALSE POSITIVE REACTIONS; HUMANS; RETROSPECTIVE STUDIES; RISK;

EID: 84877710697     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12074     Document Type: Article

References (18)

1. Klemola E, Kaariainen L,. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis. Br Med J 1965; 2: 1099-1102.
2. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG,. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981; 98: 281-287.
3. Bowden RA, Sayers M, Cays M, Slichter SJ,. The role of blood product filtration in the prevention of transfusion associated cytomegalovirus (CMV) infection after marrow transplant. Transfusion 1989; 29 (Suppl.): 57S.
4. Söderberg-Naucler C, Fish KN, Nelson JA,. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus- permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest 1997; 100: 3154-3163.
5. Vamvakas EC,. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev 2005; 19: 181-199.
6. Ziemann M, Krueger S, Maier AB, Unmack A, Goerg S, Hennig H,. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007; 47: 1972-1983.
7. Dumont LJ, Luka J, VandenBroeke T, Whitley P, Ambruso DR, Elfath MD,. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood 2001; 97: 3640-3647.
8. Drew WL, Roback JD,. Prevention of transfusion-transmitted cytomegalovirus: reactivation of the debate? Transfusion 2007; 47: 1955-1958.
9. Ziemann M, Unmack A, Steppat D, Juhl D, Görg S, Hennig H,. The natural course of primary cytomegalovirus infection in blood donors. Vox Sang 2010; 99: 24-33.
10. Drew WL, Tegtmeier G, Alter HJ, Laycock ME, Miner RC, Busch MP,. Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion 2003; 43: 309-313.
11. Zhang C, Buchanan H, Andrews W, Evans A, Pass RF,. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol 2006; 35: 338-342.
12. Rasmussen L, Kelsall D, Nelson R, Carney W, Hirsch M, Winston D, Preiksaitis J, Merigan TC,. Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. J Infect Dis 1982; 145: 191-199.
13. Schmidt CA, Oettle H, Peng R, Neuhaus P, Blumhardt G, Lohmann R, Wilborn F, Osthoff K, Oertel J, Timm H, Siegert W,. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation 1995; 59: 1133-1138.
14. Marsano L, Perrillo RP, Flye MW, Hanto DW, Spitzer ED, Thomas JR, Murray PR, Windus DW, Brunt EM, Storch GA,. Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients. J Infect Dis 1990; 161: 454-461.
15. Halling VW, Maine GT, Groettum CM, Wilson JA, Spesard J, Brojanac S, Combs B, Wachta D, Holas C, Wilson T, Wang D, Tomazic-Allen S, Lazzarotto T, Landini MP, Jevremovic-Simovic S, Wiesner RH, Paya CV, Smith TF,. Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients. Transplantation 2001; 71: 395-397.
16. Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MD, Covington E, Alecock E,; Valganciclovir Solid Organ Transplant Study Group. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 5: 1065-1070.
17. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF,. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999; 180: 702-707.
18. Revello MG, Zavattoni M, Sarasini A, Percivalle E, Simoncini L, Gerna G,. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis 1998; 177: 1170-1175.